Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 790

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 790
---
 achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279(including aggregate accrued interest to September 30, 2014, of $ 29), issued to Valent by Del Mar (BC), for 279shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the three months ended September 30, 2024, the Company recorded $ 2(2023 - $ 2 ) related to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-OutNotice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083to Valent. As a result, the Company granted Valent a non-exclusive,fully-paid, royalty-free, perpetual, worldwide and non-transferablelicense, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083equal to 5% of Valent Net Sales (as defined in the Valent Assignment Agreement). Related party payables As of September 30, 2024, there is an aggregate amount of $ 50(June 30, 2024 - $ 52) payable to the Company’s officers and directors for fees, expenses, and other liabilities. F-39

8 Stockholders’ equity

Preferred stock

Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |         |   |     |                 |        |   |
|                                                        |     | Numberof shares          |         |   |     | $(in thousands) |        |   |
| Balance - June 30, 2024                                |     |                          |  13,668 |   |     |                 |  9,973 |   |
| Conversion of Series C Preferred stock to common stock |     |                          | (13,668 | ) |